Detalles de la búsqueda
1.
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 403(10423): 249-260, 2024 Jan 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38048786
2.
Attenuated cell cycle and DNA damage response transcriptome signatures and overrepresented cell adhesion processes imply accelerated progression in patients with lower-risk myelodysplastic neoplasms.
Int J Cancer
; 154(9): 1652-1668, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38180088
3.
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Lancet
; 402(10399): 373-385, 2023 07 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37311468
4.
Cryptic aberrations may allow more accurate prognostic classification of patients with myelodysplastic syndromes and clonal evolution.
Genes Chromosomes Cancer
; 59(7): 396-405, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32170980
5.
Differential expression of homologous recombination DNA repair genes in the early and advanced stages of myelodysplastic syndrome.
Eur J Haematol
; 99(4): 323-331, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28681469
6.
Epigenetic silencing of the oncogenic miR-17-92 cluster during PU.1-directed macrophage differentiation.
EMBO J
; 30(21): 4450-64, 2011 Sep 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-21897363
7.
Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes.
Br J Haematol
; 168(3): 361-70, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25272332
8.
Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide.
Eur J Haematol
; 95(1): 35-43, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25287904
9.
High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.
Eur J Haematol
; 95(1): 27-34, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25284710
10.
Lenalidomide treatment induced the normalization of marker protein levels in blood plasma of patients with 5q-myelodysplastic syndrome.
Gen Physiol Biophys
; 34(4): 399-406, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26001289
11.
[Lenalidomide treatment in myelodysplastic syndrome with 5q deletion--Czech MDS group experience]. / První ceské zkusenosti s lenalidomidem v terapii anemických nemocných s myelodysplastickým syndromem s delecí dlouhého ramene 5. chromozomu.
Vnitr Lek
; 61(12): 1028-33, 2015 Dec.
Artículo
en Cs
| MEDLINE | ID: mdl-26806497
12.
NQO1*2 polymorphism predicts overall survival in MDS patients.
Br J Haematol
; 184(2): 305-308, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29363755
13.
The translocation t(2;11)(p21;q23) without MLL gene rearrangement--a possible marker of good prognosis in myelodysplastic syndrome patients.
Hematol Oncol
; 32(2): 82-6, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23949951
14.
Characterization of chromosome 11 breakpoints and the areas of deletion and amplification in patients with newly diagnosed acute myeloid leukemia.
Genes Chromosomes Cancer
; 52(7): 619-35, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23580398
15.
Transcription factors Fli1 and EKLF in the differentiation of megakaryocytic and erythroid progenitor in 5q- syndrome and in Diamond-Blackfan anemia.
Ann Hematol
; 92(1): 11-8, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22965552
16.
Expression of circular RNAs in myelodysplastic neoplasms and their association with mutations in the splicing factor gene SF3B1.
Mol Oncol
; 17(12): 2565-2583, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37408496
17.
G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial.
Blood Cancer J
; 12(7): 105, 2022 07 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35798720
18.
Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways.
Cells
; 11(2)2022 01 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35053339
19.
Noncoding RNAs and Their Response Predictive Value in Azacitidine-treated Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-related Changes.
Cancer Genomics Proteomics
; 19(2): 205-228, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35181589
20.
RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS.
Leukemia
; 36(7): 1898-1906, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35505182